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A B S T R A C T
Drugs that modulate mitochondrial function can cause severe adverse effects. Unfortunately, mitochondrial
toxicity is often not detected in animal models, which stresses the need for predictive in silico approaches. In this
study we present a model for predicting mitochondrial toxicity focusing on human mitochondrial respiratory
complex I (CI) inhibition by combining structure-based methods with machine learning. The structure-based
studies are based on CI inhibition by the pesticide rotenone, which is known to induce parkinsonian motor
deficits, and its analogue deguelin. After predicting a common binding mode for these two compounds using
induced-fit docking, two structure-based pharmacophore models were created and used for virtual screening of
DrugBank and the Chemspace library. The hit list was further refined by three different machine learning
models, and the top ranked compounds were selected for experimental testing. Using a tiered approach, the
compounds were tested in three distinct in vitro assays, which led to the identification of three specific CI
inhibitors. These results demonstrate that risk assessment and hazard analysis can benefit from combining
structure-based methods and machine learning.
1. Introduction
Mitochondria are eukaryotic cell organelles which are known as the
power plants of the cells, since they are capable of producing vast
amounts of adenosine triphosphate (ATP) via oxidative phosphoryla-
tion [1]. Additionally, mitochondria are also involved in several other
metabolic processes such as fatty acid oxidation [2], iron-sulfur cluster
synthesis [3], or calcium signaling [4]. Due to their central role in
metabolism, mitochondrial dysfunction is linked to various diseases like
cancer [5], cardiovascular diseases [6], diabetes [7], liver diseases [8],
and also to neuronal diseases such as Parkinson’s or Alzheimer’s disease
[9]. Consequently, drugs that impede mitochondrial function can cause
severe adverse effects. The antidiabetic drug troglitazone, for example,
was withdrawn due to severe liver injury that was later on shown to be
linked to toxic effects on mitochondria [10]. Unfortunately, mi-
tochondrial toxicity is often not detected in animal studies as the
animals used are young, mostly rodents, and have strong mitochondrial
reserves [11].
On a molecular basis, mitochondrial toxicity of a compound is
linked to interaction with e.g. the phospholipid bilayer, the mitochon-
drial DNA (mtDNA), or the calcium uniporter [12]. However, one of the
most prominent mechanisms leading to mitochondrial toxicity is
modulation of the electron transport chain (ETC), where oxidative
phosphorylation takes place. The ETC is located in the mitochondrial
inner membrane and comprises four protein complexes (CI - IV), which
establish an electrochemical proton gradient that provides the energy
for the ATP-synthase to create ATP from ADP (adenosine diphosphate)
[13].
In risk assessment, the framework of adverse outcome pathways
(AOP) links biological/toxicological data to adverse effects [14,15].
Recently, an AOP has been published which underlines the evidence
that CI inhibition by the pesticide rotenone (1) leads to Parkinsonian
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motor deficits. In this specific AOP, the molecular initiating event is the
binding of the inhibitor to CI. Afterwards, several key events, such as
inhibition of CI, mitochondrial dysfunction, and neuro-inflammation
lead to the adverse outcome Parkinsonian motor deficits [16]. CI con-
sists of 45 subunits (44 unique protein chains) whose complete cryoEM
structure was published in 2017 (PDB ID: 5XTD, 3.7Å) [17] (Fig. 1a).
The goal of this study was to target the first key event in the AOP,
i.e. the CI inhibition, by structure-based modeling approaches.
Combining docking of compounds into the rotenone binding site at CI
with pharmacophore-based screening and machine learning led to a
workflow which could identify compounds prone to cause mitochon-
drial toxicity via CI inhibition.
The model was validated via virtual screening of two large com-
pound libraries followed by selection of twelve compounds for experi-
mental testing in three different in vitro assays. Using a tiered ap-
proach, we first assessed the perturbation of mitochondrial membrane
potential (MMP), a measure of mitochondrial integrity. Subsequently,
we assessed the substances’ hazard to be neurotoxic and mitotoxic,
using the Glc-Gal-NeuriTox test [20]. Finally, we assessed specificity
over the other respiratory complexes.
2. Materials and methods
2.1. Alignment
The binding site of rotenone in CI is located from mutation studies
in Yarrowia lipolytica. Human NDUFS2 and yeast NUCM share the same
fold and have a sequence identity of 64%. The residues mutated in the
proposed rotenone binding site (NDUFS2 and NDUFS7, D140, S143,
M185, F200, F204, V457, D455 and M94 human nomenclature and
numbering) are conserved in yeast and human CI [19]. The multiple
sequence alignment was performed using the online tool promals3D
[21,22] implementing the NDUFS2 and the NDUSF7 subunit from seven
different organisms (human, bovine, mouse, Yarrowia lipolytica, Rho-
dobacter capsulatus, Escherichia coli and Thermus thermophilus). (ESM1,
Suppl. Item 5)
2.2. Docking and clustering
Protein and ligand preparation, induced fit docking and clustering
have been performed in Maestro 2017–4 (SCHRÖDINGER), [23] using
the OPLS3 force field. Ligprep and the Protein preparation wizard were
used with default settings, with pH 7 ± 2. To generate various con-
formers of the ligands the conformational search tool has been used.
Docking has been performed, using the induced-fit docking protocol
with default settings and extended sampling. Induced-fit docking was
used to allow protein flexibility within the pocket [24]. The center of
the grid was set between the residues 140, 200, 457 in NDUFS2 of
5XTD. Docking was performed without constraints, including only the
subunits around the binding-site (chain: B, C, E, P, N, Q, j and s).
Clustering of rotenone and deguelin was performed within the con-
former clustering module according to their common scaffold.
(SMARTS:“c1cccc(c12)OC3C(C2 = O)c4c(OC3)cc(O)c(c4)O”). Clus-
tering based on Volume Overlap was performed regarding the nor-
malized volume overlap and complete as linkage method. RMSD cal-
culations were performed using the RMSD-calculation node of the
Schrödinger package in KNIME 3.6.2.
2.3. Pharmacophore modeling and virtual screening
Pharmacophore modeling and virtual screening were performed in
LigandScout 4.2.1 [25,26]. The preparation of the screening libraries
was performed with the iCon module, using iCon Best (max. 200 con-
formations per compound). The screening was performed using iscreen
module, with default settings.
2.4. Machine learning models
The three machine learning models used in this study, a gradient
boosting [27], a random forest [28] and a deep learning model en-
semble [29], were recently developed by us [30]. Briefly, the models
were trained on a dataset for mitochondrial toxicity compiled from the
Tox21 dataset [31], the Zhang dataset [32], ChEMBL [33] and by lit-
erature search. In total the dataset consists of 5761 compounds (4940
actives, and 827 inactives) with the cutoff for activity set at a pChEMBL
value ≥ 5. For training the gradient boosting model the data was split
into training (80%) and test (20%) set. Further it was trained using an
extensive model selection workflow available on the KNIME 3.6.3
analytics platform on the examples server 04/Analytics/11_Optimiza-
tion/08Model_Optimisazion_and_Selection using five different type of
fingerprints (ECFC6, ECFP6, ECFP4, AtomPair and RDKit) and different
model algorithms. The optimal combination of fingerprint, algorithm,
and hyperparameters was found via a large grid search. For the deep
learning model a nested cross-validation with folds based on a previous
clustering was used to determine the best hyperparameters. The deep
learning model was trained using keras and tensorflow and the random
forest model using the scikit-learn library version 0.19.0. The random
forest model was trained with 10 RDKit descriptors and a smaller subset
of 1412 randomly chosen molecules. All three models have been vali-
dated using a common external test set. For further details see Hem-
merich, et al. [30] and also our GitHub repository https://github.com/
PharminfoVienna/Mitochondrial-Toxicity.
2.5. Compounds synthesis
Compounds 3–14, were bought from Enamine (https://enamine.
net/), where they were synthesized (Catalogue numbers: Z1550449875,
Z1417029922, Z33474488, Z28738114, Z2666334399, Z2647724547,
Z2222823426, Z1748268470, Z1840858432, Z1728504684). All of the
compounds reported in the manuscript have a purity of ≥ 95% (except
13, 91%).
Fig. 1. CryoEM structure of CI (PDB ID 5XTD [17]). a The complex is divided
into a membrane arm, were proton pumps are located, and into the matrix arm
where the ubiquinone binding site is located [18]. The inhibitor binding site is
located next to the ubiquinone binding site at the interface of the sub units
NDUFS2 and NDUFS7 [19]. b The pesticides and CI inhibitors rotenone (1) and
deguelin (2).
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2.6. HepG2 cell culture
The HepG2 cell line was maintained in complete medium consisting
of DMEM (Dulbecco’s modified Eagle’s medium, Fisher Scientific), 10%
FBS (fetal bovine serum, South American Fisher Scientific) and peni-
cillin/streptomycin (respectively 25U/ml and 25 µg/ml, Fisher
Scientific). Cells were kept at 37 °C and 5% CO2.
2.7. Mitochondrial membrane potential assay in HepG2
Cells were seeded at a density of 10.000cell/well in a black µclear
plate (384-wells, Greiner Bio-One). Upon 48 h the nuclei were loaded
with Hoechst-33342 (200 ng/ml, life technologies) and Rhodamine123
(rho123, 1 µM, Sigma Aldrich). After 75 min of incubation the medium
was replaced with medium containing rho123 (0.2 µM) and propidium
iodide (100 nM). Subsequently cells were exposed to a concentration
range of the chemicals. The Hoechst, rho123 and PI signal intensity
(respectively 408, 488 and 561 nm laser) was tracked for 24 h every
hour using a high throughput imaging platform (Nikon TiE200 with
perfect focus system and automated stage; Nikon Amsterdam, The
Netherlands).
The obtained images of the 3 dyes were analysed using CellProfiler
(version 2.2.0 broad institute, Cambridge USA). The used pipeline was
built based on a previous workflow in CellProfiler [34]. The Hoechst
intensity was used to identify single nuclei (segmentation module) [35].
Rho123 intensity was assessed in the cytoplasm, which was segmented
as a distance of 5 pixels around the nucleus. Finally, cell death was
assessed as the fraction of nuclei that were both positive for the Hoechst
and PI signal. The obtained intensity values per cell were stored in a
HDF5file. Membrane potential values are represented as an average per
picture of the integrated pixel intensity of all identified nuclei and re-
lated cytoplasms.
2.8. LUHMES cell culture
LUHMES (Lund human mesencephalic) cells were maintained as
proliferating precursor cells, using proliferation medium (Advanced
DMEM/F12 supplemented with 2 mM L-glutamine, N2 supplement (1X,
all Invitrogen) and 40 ng/ml human fibroblast growth factor (FGF,
R + D systems)), and incubated with 5% CO2 at 37 °C. Cells were
passaged every two to three days [36]. For LUHMES cell differentiation,
cells were seeded in proliferation medium with a density of 45,700
cells/cm2. After 24 h, the medium was exchanged to differentiation
medium (Advanced DMEM/F12 supplemented with 2 mM L-glutamine,
1x N2 (all Invitrogen), 1 mM cAMP (Sigma-Aldrich), 1 µg/ml tetra-
cycline (Sigma-Aldrich) and 2 ng/ml recombinant human glial cell-
derived neurotrophic factor (GDNF, R + D Systems)). For the genera-
tion of differentiating galactose cells, parallel cultures were generated
that received glucose-free (instead of 18 mM), differentiation medium
that was supplemented with 18 mM galactose (Gal) (Roth) [20].
2.9. Glucose-Galactose-NeuriTox test
LUHMES cells were differentiated for 48 h (d2), detached with
0.05% trypsin/EDTA (Invitrogen) and seeded into 96 well plates at a
density of 100,000 cells/cm2. One hour after seeding (i.e. after at-
tachment), the cells were treated for 24 h with the test substances. On
d3, cells were life-stained with 1 µg/ml Hoechst H-33342 and 1 µM
calcein-AM. Automated microscopy and high-content image analysis
was performed to identify viable cells (Hoechst and calcein double-
positive), dead cells (Hoechst single-positive), relative viability
(V = life cell count/total cell count) and the corresponding neurite area
(NA). The NA was calculated as described before (Di et al., 2012; Wink
et al., 2017). In brief, from the total calcein-positive area, the somatic
area was subtracted, which was identified by expansion of the nuclear
region). Concentration response curves were obtained and fitted using a
4-parameter Hill function with the upper and lower asymptote con-
strained to 0% and 100%, respectively. Substances were classified to be
specifically neurotoxic, if their EC25ratio (V/NA) was in either or both
of the media ≥ 4. Substances were classified to be specific mitochon-
drial toxicants, if their ratio of neurite outgrowth impairment between
Glc and Gal condition was ≥ 2 (EC25NA(Glc/Gal)) [20,37].
2.10. Seahorse mitochondrial CI and III activity analysis
For the analysis of CI and CIII activity/inhibition, proliferating
LUHMES cells were seeded into Seahorse 24 well plates at a density of
205,000 cells/cm2 one day before the assay in proliferation medium.
The assay was started by permeabilization of the cells using MAS-buffer
(70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2,
2 mM HEPES, 1 mM EGTA, 4 mg/ml fatty acid free BSA; pH = 7.2)
supplemented with 1 mM ADP and 25 µg/ml digitonin, for 13 min di-
rectly before starting the Seahorse measurements. CI and III activity
was assessed by monitoring the oxygen consumption rate (OCR) before
and after injection of the test substances and complex-specific sub-
strates and inhibitors in parallel between test substance treated wells
and solvent-control treated wells. As CI substrate, 5 mM pyruvate,
2 mM L-glutamine and 2.5 mM malate was used. To fuel CIII, 250 µM
duroquinol, 1 µM rotenone (CI inhibitor) and 5 mM malonate (CII in-
hibitor) were used. To assess the non-mitochondrial respiration, 0.5 µM
antimycin A and 0.5 µM rotenone were injected. Mitochondrial activity
(i.e. OCR) was defined to be the total OCR subtracted by the non-mi-
tochondrial OCR, always using values relative to solvent control. The
relative complex inhibition was calculated as 100% - activity.
3. Results and discussion
3.1. Identification of new CI inhibitors by structure-based design
The binding pocket was identified based on residues known from
previously published mutations in Yarrowia lipolytica at the interface of
NDUFS2 and NDUFS7. In this study, residues were mutated in order to
impair the physicochemical properties and shape of the binding site.
The study presents mutations which lead to a loss of the inhibitory
potency of rotenone (D143A, S146C, M188C, F203E, D458A, V460L
and M91C (yeast numbering)) [19]. Thus we hypothesized that these
residues were essential for the binding of rotenone (1). For creating
binding mode hypotheses for rotenone and its structural analogue de-
guelin (2), we performed induced-fit docking of both compounds into
the human CI (PDB ID 5XTD (17)). The 521 poses (109 for deguelin,
412 for rotenone) retrieved from induced-fit docking were clustered
according to their common scaffold [38,39], which led to four clusters
containing rotenone as well as deguelin poses (ESM1, Suppl. Item 1).
For each of the four clusters, the root mean square deviation (RMSD)
between rotenone and deguelin poses was calculated. The poses were
ranked according their RMSD and their docking score (XP GScore),
followed by visual inspection of the poses. In the final proposed binding
mode (Fig. 2), the deguelin pose is the best scored deguelin pose and
the rotenone pose is within the top 100 of 412 rotenone poses. The
RMSD between the two poses is 0.257 Å and for both, rotenone and
deguelin, hydrogen bonding between the methoxy groups and T83 and
G85 of NDUFS7 can be observed. Furthermore, both rotenone and de-
guelin poses were located in the second most populated cluster (74
poses; 20 deguelin, 54 rotenone), which also contains the best scored
rotenone and deguelin poses.
The proposed common binding mode of rotenone and deguelin was
then used to create two structure-based pharmacophore models, using
LigandScout 4.2.1 (Fig. 3). First, a very specific model, containing nine
features and a dense excluded volume coat, which is referred to as
pharmacophore A, and, second, a less specific model containing only
five fixed and one optional feature with a less dense excluded volume
coat, which is referred to as pharmacophore B. The optional feature
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only catches deguelin but not rotenone. However, it was included in
pharmacophore B to gain a higher specificity of the model.
Subsequently, the two models were used for virtual screening of
DrugBank (DB) release 5-1-1 [40] and Chemspace (CS) release Feb.
2018 (“https://chem-space.com/”). DrugBank was selected for
screening to cover available and possible drugs. In fact, this library
contains approximately 6000 compounds which are either drugs,
withdrawn drugs or experimental drugs. Conversely, Chemspace con-
tains approximately 50 million compounds and was chosen to cover a
larger chemical space. As expected, pharmacophore A (CS 438 hits, DB
1 hit - rotenone) was much more selective than pharmacophore B (CS
105,090 hits, DB 18 hits) and therefore retrieved less hits.
3.2. Refinement of the hit list by machine learning models
To include ligand-based information and to refine the hit list using a
methodologically different method, the retrieved hits were subjected to
three distinct machine learning models, a gradient boosting, a random
forest and a deep learning model, developed recently by us (see mate-
rials and methods and (30)). Each compound which was hit by one of
the two pharmacophores, was predicted either “toxic”, assigned as 1, or
“nontoxic”, assigned as 0, in each of the models. Further, this in-
formation was used for hit list refinement.
To validate the approach of combined structure-based toxicity
prediction and machine learning, twelve compounds (3–14) were se-
lected for experimental testing. For compound selection, we considered
hits retrieved from DrugBank (pharmacophore B) and from Chemspace
(pharmacophore A). Out of the 18 hits retrieved from DrugBank, nine
were predicted to be active by at least one of the machine learning
models. Unfortunately, only compounds 9 and 14 were commercially
available and were thus subject to experimental testing. The hits re-
trieved from screening Chemspace (pharmacophore A) were ranked
regarding their pharmacophore fit score and their prediction in the
machine learning models using the Pareto-ranking node in KNIME
3.6.2. The five subsets constituting the deep learning model were taken
into account separately to implement the predictions of each subset in
the ranking. Subsequently, considering also commercial availability
and pricing, ten of the top ranked compounds were selected for ex-
perimental testing (Table 1). Applying the Pareto-ranking, all models
(pharmacophore fit score and machine learning models) were weighted
identically. Hence, e.g. 3 and 11 were selected due to their predicted
activity in the machine learning models, 5 on the other hand, due to the
high pharmacophore fit score (96.51). The selected compounds (3–14)
were subjected to in vitro testing and validation of their predicted mode
of action, i.e. CI inhibition.
3.3. Experimental testing of hits from virtual screening
Using a tiered approach, we first assessed the MMP, a measure of
mitochondrial integrity. Second, since mitochondrial CI-inhibitors may
trigger Parkinsonian motor deficits [16], we went further using a
neuronal cell line, often used in parkinsonism research and applied the
Glc-Gal-NeuriTox test [20]. Additionally, we intended to be more spe-
cific on the mechanism and the adverse outcome. Thus, in the third
assay, we assessed the impairment of mitochondrial respiratory chain
function to specifically test for CI inhibition.
3.4. Assessment of mitochondrial membrane potential
Chemical-induced mitochondrial perturbation can be assessed in
cellular systems based on effects upon mitochondrial integrity. One way
to quantify mitochondrial integrity is to monitor the presence of the
Fig. 2. Proposed common binding mode of 1 (pink sticks) and 2 (blue sticks). Overall structure of CI show in grey cartoon, the binding site is colored in pink. Close up
of the binding site on the right side of the panel. The hydrogen bonds to T83 and G85 are shown in dashed lines in light pink and blue. The NDUFS2 unit is colored in
turquoise and the NDUFS7 in pink (dark for rotenone and light for deguelin pose).
Fig. 3. Shared pharmacophores of rotenone and deguelin. The spheres depict
the features of the pharmacophore. Red represents hydrogen bond acceptors,
yellow hydrophobic regions and the cylinder aromatic features, excluded vo-
lume coats are not depicted here for clarity. Rotenone is coloured in pink and
deguelin in blue. a Pharmacophore A, consists of six hydrogen bond acceptors,
two hydrophobic and one aromatic feature. b Pharmacophore B, consists of
three hydrogen bond acceptors and three hydrophobic features, the feature
which is optional is depicted in small dots.
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MMP between the intermembrane space and the mitochondrial matrix.
This method relies on the accumulation of membrane potential-de-
pendent dyes into the negative charged matrix. Using a tiered approach,
first the assessment of a general effect upon mitochondrial integrity can
be performed using the HepG2 cell line, which is a cell line suitable for
early and quick screening (Fig. 4a, b and c). Evaluation of the effects on
MMP in a concentration and time dependent manner provides the first
evidence for the identification of mitochondrial toxicants and possible
Table 1
Scoring of 3–14.
Nr[a] Depiction[b] Pharmacophore fit score[c] Models predicted active (out of 7)[d] Database[e]
3 95.97 3 CS
4 96.23 3 CS
5 96.5 1 CS
6 96.48 1 CS
7 95.72 3 CS
8 95.84 3 CS
9 56.57 2 DB
10 96.58 2 CS
11 95.84 3 CS
12 96.35 1 CS
13 96.55 3 CS
14 56.39 4 DB
[a] Compound identifier.
[b] Depiction of the molecule.
[c] Score of the pharmacophore fitting in the virtual screening.
[d] Positive prediction in the machine learning models. For this analysis the deep learning model was split to its 5 subsets.
[e] Database the compound belonged to. DrugBank (DB), Chemspace (CS).
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parkinsonian liabilities via CI interference (Fig. 4d).
All 12 identified possible CI inhibitors were assessed in a con-
centration range from 0.0025 µM to 50 µM over a period of 24 h for
their effects on the MMP (Fig. 4e, f). Notably, none of the substances
was toxic in the used assay settings (PI values not shown). The positive
controls deguelin and rotenone affected the MMP already after 2 h
exposure at low µM concentrations. Furthermore, the IC values of both
demonstrated a shift of 10-fold at 24 h. Of the assessed new set of
chemicals only 10 did not affect mitochondrial integrity in the tested
concentration range. 3, 4 and 6 perturbed the MMP at high nM ranges
and 5, 8 and 11 affected the MMP in the low µM range. None of the
chemicals demonstrated the ~ 10-fold difference in IC values between
the early and late time points that was observed for deguelin and ro-
tenone exposure (Fig. 4f). Overall, of the selected 12 chemicals, three
(3, 4 and 6) perturbed the MMP at concentrations similar to deguelin
and rotenone.
3.5. Screening for potential mitochondrial toxicants applying the Glc-Gal-
NeuriTox test
The Glc-Gal-NeuriTox test was applied to identify specific mi-
tochondrial toxicants (mitotoxicants). This test relies on the metabolic
reprogramming of LUHMES cells under different (glucose (Glc) vs ga-
lactose (Gal)) medium sugar conditions (Fig. 5a). In the Gal-condition,
the neuronal cells show a predominant mitochondrial phenotype,
making them especially sensitive for mitotoxicants. By evaluating the
neurite outgrowth, an energy-consuming and neuro-specific process, in
parallel with general cell viability by automated high content imaging
(Fig. 5b), specific neurotoxicants can be identified as well. The classi-
fication of the test substance as either neurotoxic and/or mitotoxic,
depends on the effective concentration that impairs the assessed mea-
sures (Fig. 5c). The tested substances can either be (i) inactive (ef-
fects ≤ 25%), (ii) unspecifically cytotoxic (i.e. reduction of neurite area
and viability at similar concentrations), (iii) specific neurotoxicants (i.e.
impairment of neurite outgrowth at lower concentrations than viabi-
lity), (iv) specific mitotoxicants (i.e. stronger effects in Gal than in Glc
condition), or (v) specific neuro- and mitotoxicants.
Each compound was assessed at ≥ 10 different concentrations in
three independent experiments. 4 was identified to be a specifically
neurotoxic compound, but likely to be not interfering with mitochon-
drial metabolism (Fig. 5d). In contrast, 5 was identified to be strongly
neuro- and mitotoxic (i.e. different toxicity in Glc and Gal). Also 11 was
identified to be mitotoxic (Fig. 5e). 14 was strongly cytotoxic without
indicating a specific mitochondrial- or neuronal toxicity. For 3, no exact
prediction could be made within the concentration range tested. At the
highest tested concentration, the EC25 for neurite outgrowth impair-
ment was reached in Gal conditions, while in Glc this parameter was
not affected. These data suggest that 3 may be mitotoxic, but further
data would be required for confirmation.
Fig. 4. MMP assessment as measure for mitochondrial perturbation. The maintenance of MMP can be used as a measure for mitochondrial perturbation, which can be
assessed using a mitochondrial specific, membrane potential-dependent dye: Rhodamine123. a A schematic representation of the assay set up: HepG2 cells are seeded
in the desired format 48 before chemical exposure. The cells are loaded with Rho123 dye followed by a second lower concentration of Rho123 and PI staining after
75 min and just before chemical exposure. The effects upon MMP is monitored for 24 h every hour. b Representative pictures of two conditions: vehicle control (0.1%
DMSO) and 4 [50 µM]. c Example (cropped) picture of intensity pictures and the object segmentation performed in CellProfiler. d Concentration time curve of 4 over
24 h at 3 concentrations normalized to the vehicle control (1 biological replicate). e Concentration response curves of the rho123 intensity normalized to the vehicle
control at 24 h of chemical exposure (the curves are 3 biological replicates with 2 technical replicates each +/- SD) (F) IC25 values at 2 and 24 h chemical exposure
(3–14) and the two positive controls 1 and 2 (for 1 and 2, IC25 are calculated from data taken from v.d.Stel, Carta, et al., unpublished results).
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3.6. Assessing the impairment of mitochondrial respiratory chain function
Screening in the Glc-Gal-NeuriTox test suggested that substances 5,
11 (and 3) may indeed inhibit CI. To assess this directly, LUHMES cells
were permeabilized to make their mitochondria accessible. By mon-
itoring CI-mediated oxygen consumption at CIV (via feeding CI sub-
strates pyruvate, malate and glutamine), CI activity was assessed
(Fig. 6a). Indeed, substances 3, 5 and 11 were the only substances that
Fig. 5. Glucose-Galactose-NeuriTox screen to identify potential mitochondrial inhibitors. The Glc-Gal-NeuriTox test is based on the modulation of the neurite
outgrowth of LUHMES (human dopaminergic neuronal) cells, and can be used to identify specific neuro- and/or mito-toxicants. a Neuronal differentiation from
proliferating precursors is performed for 48 h (two days), before cells are re-plated into 96 well plates and treated with test substances for 24 h. On day 3 of
differentiation, the assay readout is performed by high content imaging and automated analysis. By testing two conditions in parallel that favor either glycolytic
(glucose (Glc) condition) or mitochondrial metabolism (galactose (Gal) condition), mitochondrial toxicants can be identified by an increased toxicity in the Gal/
mitochondrial condition. b Automated high content imaging is used to record pictures of nuclei (stained with H-33342) and neuronal cytoplasm (stained by calcein-
AM) including neurites and cell bodies (somata). An automated algorithm identifies the nuclei, determines the somatic area and subtracts the latter from the total
calcein-positive area to obtain the neurite area (NA, red mask). In parallel, viability (V) of the investigated cultures is determined by evaluating the single/double
staining for H-33342 and calcein. Only life cells are double positive (encircled green), while dead cells are encircled pink. Example pictures of the DMSO solvent-
control (0.1% (V/V)), the two left images have a width of 330 µm, the two right enlargements have a width of 165 µm. c The prediction model makes use of the
effective concentrations (EC) that are necessary to reduce viability (V) or neurite area (NA) by 25% relative to control, and classifies the test substances as specific
neurotoxicant (n) and/or specific mitotoxicants (m) if applicable. d Exemplary data of test compound effects on V and NA in the presence of Glc or Gal. 4 exemplifies
a neurotoxic (n) compound, while 5 was neurotoxic and mitotoxic (m, n; strong difference of NA-Glc and NA-Gal). The gray areas indicate concentrations above the
solubility limit. e Summary data of the Glc-Gal-NeuriTox test for all 12 hit substances (3–14) and the two positive controls rotenone and deguelin (1 and 2), for the
latter two data are taken from (20).
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inhibited CI significantly, i.e. beyond the noise band of 20%. 5 was the
most efficient substance, by reducing CI activity by ca. 40% at 7 µM
tested (i.e. the EC25NA,Gal), 11 was tested at 35 µM (its EC25NA,Gal), at
which it reduced CI activity by ca. 25%. 3 was tested at 40 µM (its
EC25NA,Gal) and reduced CI activity as well by ca. 25% (Fig. 6b). In
order to exclude that the test substances inhibited a complex down-
stream of CI that might cause an “apparent CI inhibition”, we in-
vestigated CIII activity, the complex directly downstream of CI. Neither
3, 5 nor 11 showed a significant (> 20%) inhibition of CIII. Thus we
concluded that neither CIII, nor downstream complexes (i.e. CIV or CV)
were affected by the test substances (Fig. 6c). In summary, 3 of the 12
hit compounds can be classified as bona fide CI inhibitors. The initial
results from the Glc-Gal-NeuriTox screen were completely confirmed by
the more detailed mechanistic investigation. Moreover, the two most
efficient inhibitors, 5 and 11, were subjected to detailed con-
centration–response analysis for their inhibitory effect on CI. IC25
concentrations for these compounds were 7.9 and 56 µM, respectively,
confirming the prior observed offset in efficacy at the single con-
centration tested (Fig. 6d). Although both substances inhibited CI ac-
tivity by ca. 65%-75%, a full inhibition of CI activity could not be ob-
served within the soluble concentration range.
3.7. Docking of the in vitro tested compounds
Compounds 3–14 were docked into human CI (PDB ID 5XTD). To
exclude any bias from the rotenone and deguelin pose, induced-fit
docking was performed into the apo structure. The binding site, as well
as the settings for docking were chosen in the same way as for docking
rotenone and deguelin (Experimental Section). Since in this case the
compounds do not share a common scaffold, the 269 poses retrieved
were clustered according to their volume overlap, which resulted in 14
clusters. Six clusters contain only inactives, three clusters comprise both
actives and inactives, and five clusters contain only actives. (ESM1
Suppl. Item 2) The latter were analysed further using XP Gscore, ligand
protein interactions, as well as visual inspection in order to propose
binding modes for the actives 3, 5 and 11 (Fig. 7).
As expected, the selected binding pose of the most potent inhibitor 5
(IC25 of 7.9 µM) overlays better to the proposed binding mode of ro-
tenone and deguelin (Fig. 7d), than the pose of 11 (IC25 of 56 µM)
(Fig. 7e). Since 5 is the only compound of the three newly discovered
specific CI inhibitors showing also specific neurotoxicity in the Neur-
iTox test, we hypothesize that it might be the most likely one triggering
the AOP that leads to Parkinsonian motor deficiencies as adverse out-
come.
4. Conclusion
By combining structure-based methods and machine learning a re-
fined hit-list of 12 potential CI inhibitors (3–14) was retrieved. The
MMP was decreased by 3, 4 and 6 at high nM concentrations and by 5,
8 and 11 in the low µM range. In vitro screening in the Glc-Gal-
NeuriTox test identified that the substances 3, 5 and 11 were most
likely mitochondrial toxicants. Direct assessment of CI inhibition in
LUHMES neurons showed that these three substances were genuine CI
inhibitors. The potency ranking within the newly identified CI in-
hibitors is as follows: 3 (weak) < 11 (medium) < 5 (strong CI in-
hibitor). Hence, we were able to identify key event ligands for the AOP
inhibition of CI in neurons leading to parkinsonian motor deficits, by
Fig. 6. Inhibition of mitochondrial respiratory chain complex activity. a To directly assess the activity of each mitochondrial respiratory chain complex, LUHMES
cells were selectively permeabilized with digitonin and fed with specific substrates and inhibitors to monitor CI and CIII activity. The diagram illustrates that if the
test for CIII activity showed no effect (≤20% change from baseline), then CIII-V were not affected by the test compound (serial connection of these complexes).
Inhibition of CI (by > 20%) was assessed in a separate assay. b CI activity in the presence of test compounds was performed at concentrations corresponding to the
EC25(NA,Gal). If this was not possible, 50 µM (i.e. 1:1000 of the stock concentration, resulting in 0.1% DMSO) were used. Each point represents an independent
experiment. c For the substances that showed a CI inhibition, CIII activity was quantified (via oxygen consumption at CIV, initiated by providing the CIII substrate
duroquinol) to ensure specificity. Tested concentrations were the same as in b, each point represents an independent experiment. d The most effective CI inhibitors (5
and 11) were tested at different concentrations for their effect on CI and CIII. Concentrations that inhibited CI-mediated respiration by 25% or 50% relative to control
are indicated. Data are means ± SEM; N = 3 (for CI data of 5 and 11, and CIII data of 5), N = 2 for CIII of 11), N: independent experiments (not technical
replicates).
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using a structure-based approach followed by hit refinement via ma-
chine learning models. This allowed to combine the predictive power of
machine learning with the interpretability of docking poses. Once the
method is developed and validated, it could be implemented also for
other AOPs, paving the way for a more structure-based view on the
prediction of complex toxicological endpoints.
Declaration of Competing Interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper.
Acknowledgements
This work was supported by the Land-BW (INVITE, NEURODEG),
the BMBF (e:ToP program, NeuriTox), UKN/DFG (KoRS-CB) and the
Projects from the European Union's Horizon 2020 research and in-
novation programme EU-ToxRisk (grant agreement No 681002) and
ENDpoiNTs (grant agreement No 825759).
Author Contributions.
F.T. performed all computational studies; J.D., M.F. and W.S. per-
formed the in vitro assays; C.C., M.L. B.W. and G.E. supervised the
studies. All authors contributed to writing the manuscript.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.comtox.2020.100123.
References
[1] D.F. Wilson, Oxidative phosphorylation: regulation and role in cellular and tissue
metabolism, J. Physiol. 595 (23) (2017) 7023–7038.
[2] M. Wajner, A.U. Amaral, Mitochondrial dysfunction in fatty acid oxidation
disorders: insights from human and animal studies, Biosci. Rep. 36 (1) (2016)
e00281.
[3] R. Lill, B. Hoffmann, S. Molik, A.J. Pierik, N. Rietzschel, O. Stehling, et al., The role
of mitochondria in cellular iron–sulfur protein biogenesis and iron metabolism,
Biochim. Biophys. Acta BBA – Mol. Cell. Res. 1823 (9) (2012) 1491–1508.
[4] Q. Huang, H. Cao, L. Zhan, X. Sun, G. Wang, J. Li, et al., Mitochondrial fission forms
a positive feedback loop with cytosolic calcium signaling pathway to promote au-
tophagy in hepatocellular carcinoma cells, Cancer Lett. 10 (403) (2017) 108–118.
[5] Y. Zhu, A.E. Dean, N. Horikoshi, C. Heer, D.R. Spitz, D. Gius, Emerging evidence for
targeting mitochondrial metabolic dysfunction in cancer therapy, J. Clin. Invest.
128 (9) (2018) 3682–3691.
[6] M. Bonora, M.R. Wieckowski, D.A. Sinclair, G. Kroemer, P. Pinton, L. Galluzzi,
Targeting mitochondria for cardiovascular disorders: therapeutic potential and
obstacles, Nat. Rev. Cardiol. 16 (1) (2019) 33–55.
[7] R. Blake, I.A. Trounce, Mitochondrial dysfunction and complications associated
with diabetes, Biochim. Biophys. Acta BBA – Gen. Subj. 1840 (4) (2014 Apr 1)
1404–1412.
[8] A. Mansouri, C.-H. Gattolliat, T. Asselah, Mitochondrial Dysfunction and Signaling
in Chronic Liver Diseases, Gastroenterology 155 (3) (2018) 629–647.
[9] P. Coskun, J. Wyrembak, S. Schriner, H.-W. Chen, C. Marciniack, F. LaFerla, et al., A
Mitochondrial Etiology of Alzheimer and Parkinson Disease, Biochim. Biophys.
Acta, Gen. Subj. 1820 (5) (2012) 553–564.
[10] M. Segawa, S. Sekine, T. Sato, K. Ito, Increased susceptibility to troglitazone-in-
duced mitochondrial permeability transition in type 2 diabetes mellitus model rat,
J. Toxicol. Sci. 43 (5) (2018) 339–351.
[11] Y. Will, J. Dykens, Mitochondrial toxicity assessment in industry – a decade of
technology development and insight, Expert Opin. Drug Metab. Toxicol. 10 (8)
(2014) 1061–1067.
[12] J.N. Meyer, J.H. Hartman, D.F. Mello, Mitochondrial Toxicity, Toxicol. Sci. 162 (1)
(2018) 15–23.
[13] R. Guo, J. Gu, S. Zong, M. Wu, M. Yang, Structure and mechanism of mitochondrial
electron transport chain, Biomed J. 41 (1) (2018) 9–20.
[14] M. Leist, A. Ghallab, R. Graepel, R. Marchan, R. Hassan, S.H. Bennekou, et al.,
Adverse outcome pathways: opportunities, limitations and open questions, Arch.
Toxicol. 91 (11) (2017) 3477–3505.
[15] A. Bal-Price, P.J. Lein, K.P. Keil, S. Sethi, T. Shafer, M. Barenys, et al., Developing
and applying the adverse outcome pathway concept for understanding and pre-
dicting neurotoxicity, Neurotoxicology 59 (2017) 240–255.
[16] A. Terron, A. Bal-Price, A. Paini, F. Monnet-Tschudi, S.H. Bennekou, K. Angeli,
et al., An adverse outcome pathway for parkinsonian motor deficits associated with
mitochondrial complex I inhibition, Arch. Toxicol. 92 (1) (2018) 41–82.
[17] R. Guo, S. Zong, M. Wu, J. Gu, M. Yang Architecture of Human Mitochondrial
Respiratory Megacomplex I2III2IV2 Cell(Cambridge,Mass) [Internet]. 2017 [cited
2017 Nov 6]; Available from: https://www.rcsb.org/pdb/explore/explore.
do?structureId=5XTD.
Fig. 7. Poses of the CI actives (3, 5 and 11) retrieved by induced fit docking. The NDUFS2 unit is colored in turquoise and the NDUFS7 in pink, the ligand is colored in
grey sticks. a Predicted binding mode for 3. The selected pose belongs to the cluster with the second most poses of 3 and is the fifth best scored pose. The pose shows
hydrogen bonding to T189 and backbone interactions with I456 b predicted binding mode for 5. The pose shown belongs to the cluster containing most of the poses
of 5. In addition, it is also the second best scored pose; it shows hydrogen bonding to Y141 and backbone interactions with I456. c All poses for 11 were located in the
same cluster. Here the best ranked pose is shown with backbone interactions to H92 and F458. The two most potent inhibitors 5 d and 11 e are shown superimposed
to 1 and 2, represented in pink and blue sticks.
F. Troger, et al. Computational Toxicology 14 (2020) 100123
9
[18] H. Angerer, K. Zwicker, Z. Wumaier, L. Sokolova, H. Heide, M. Steger, et al., A
scaffold of accessory subunits links the peripheral arm and the distal proton-
pumping module of mitochondrial complex I, Biochem. J. 437 (2) (2011 Jul 15)
279–288.
[19] U. Fendel, M.A. Tocilescu, S. Kerscher, U. Brandt, Exploring the inhibitor binding
pocket of respiratory complex I, Biochim. Biophys. Acta BBA - Bioenerg. 1777 (7)
(2008) 660–665.
[20] J. Delp, M. Funke, F. Rudolf, A. Cediel, S.H. Bennekou, W. van der Stel, et al.,
Development of a neurotoxicity assay that is tuned to detect mitochondrial tox-
icants, Arch. Toxicol. 93 (6) (2019) 1585–1608.
[21] J. Pei, B.-H. Kim, N.V. Grishin, PROMALS3D: a tool for multiple protein sequence
and structure alignments, Nucleic Acids Res. 36 (7) (2008) 2295–2300.
[22] J. Pei, N.V. Grishin, PROMALS: towards accurate multiple sequence alignments of
distantly related proteins, Bioinformatics 23 (7) (2007) 802–808.
[23] Schrödinger Release 2017-4: Maestro, Schrödinger, LLC, New York, NY, 2017.
[24] W. Sherman, T. Day, M.P. Jacobson, R.A. Friesner, R. Farid, Novel Procedure for
Modeling Ligand/Receptor Induced Fit Effects, J. Med. Chem. 49 (2) (2006)
534–553.
[25] G. Wolber, A.A. Dornhofer, T. Langer, Efficient overlay of small organic molecules
using 3D pharmacophores, J. Comput. Aided Mol. Des. 20 (12) (2006) 773–788.
[26] G. Wolber, T. Langer, LigandScout: 3-D Pharmacophores Derived from Protein-
Bound Ligands and Their Use as Virtual Screening Filters, J. Chem. Inf. Model. 45
(1) (2005) 160–169.
[27] J.H. Friedman, Greedy Function Approximation: A Gradient Boosting Machine,
Ann. Stat. 29 (5) (2001) 1189–1232.
[28] L. Breiman, Random Forests, Mach Learn. 45 (1) (2001) 5–32.
[29] Y. LeCun, Y. Bengio, G. Hinton, Deep learning, Nature 521 (7553) (2015) 436–444.
[30] J. Hemmerich, F. Troger, B. Füzi, G.F. Ecker. Using machine learning methods and
structural alerts for prediction of mitochondrial toxicity. Mol Inform [Internet].
[cited 2020 Mar 5];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/
abs/10.1002/minf.202000005.
[31] Tox21, “Tox21 Data Challenge 2014,” can be found under https://tripod.nih.gov/
tox21/challenge/. 2014.
[32] H. Zhang, Q.-Y. Chen, M.-L. Xiang, C.-Y. Ma, Q. Huang, S.-Y. Yang, In silico pre-
diction of mitochondrial toxicity by using GA-CG-SVM approach, Toxicol. Vitro Int.
J. Publ. Assoc. BIBRA. 23 (1) (2009 Feb) 134–140.
[33] Nucl. Acids Res. 45 (D1) (2017) D945–D954.
[34] S. Wink, S. Hiemstra, B. Herpers, B. van de Water, High-content imaging-based
BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities, Arch.
Toxicol. 91 (3) (2017) 1367–1383.
[35] Z. Di, B. Herpers, L. Fredriksson, K. Yan, B. van de Water, F.J. Verbeek et al.
Automated Analysis of NF-κB Nuclear Translocation Kinetics in High-Throughput
Screening. PLoS ONE [Internet]. 2012 Dec 27 [cited 2019 Aug 5];7(12). Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531459/.
[36] D. Scholz, D. Pöltl, A. Genewsky, M. Weng, T. Waldmann, S. Schildknecht, et al.,
Rapid, complete and large-scale generation of post-mitotic neurons from the human
LUHMES cell line, J. Neurochem. 119 (5) (2011) 957–971.
[37] J. Delp, S. Gutbier, S. Klima, L. Hoelting, K. Pinto-Gil, J.-H. Hsieh, et al., A high-
throughput approach to identify specific neurotoxicants / developmental toxicants
in human neuronal cell function assays, ALTEX - Altern Anim Exp. 35 (2) (2018)
235–253.
[38] Klepsch F, Chiba P, Ecker GF. Exhaustive Sampling of Docking Poses Reveals
Binding Hypotheses for Propafenone Type Inhibitors of P-Glycoprotein. PLoS
Comput Biol [Internet]. 2011 May 12 [cited 2019 Aug 28];7(5). Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093348/.
[39] L. Richter, C. de Graaf, W. Sieghart, Z. Varagic, M. Mörzinger, I.J.P. de Esch, et al.,
Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site
ligands, Nat. Chem. Biol. 8 (5) (2012) 455–464.
[40] Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a
major update to the DrugBank database for 2018. Nucleic Acids Res. 2018, 46
(Database issue):D1074–82.
F. Troger, et al. Computational Toxicology 14 (2020) 100123
10
